CD34 evaluation of microvasculature in lung adenocarcinoma and its microvascular density predicts postoperative tumor recurrence
Pathology and Oncology Research · 2025
DOI: 10.3389/pore.2025.1611985 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology and Oncology Research, 2025. Verfasst von Zijian Qiu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Antigens, CD34, Neoplasm Recurrence, Local, Lung Neoplasms, Neovascularization, Pathologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Angiogenesis is closely associated with tumor growth and metastasis, and microvascular density (MVD) is currently the clinical standard for evaluating tumor angiogenesis. Thus, the detection of intratumoral MVD is of great significance for understanding disease progression and predicting patient prognosis.
Methods
Tumor tissue sections of 238 patients with lung adenocarcinoma (LUAD) who underwent radical surgery were retrospectively analyzed. Immunohistochemical (IHC) staining was carried out using a CD34 polyclonal antibody to determine intratumoral MVD, and the relationship of CD34-MVD with the clinicopathological characteristics and survival time of LUAD patients was analyzed.
Results
CD34-MVD was associated with tumor size, lymph node metastasis, tumor recurrence, and patient survival status; patients with tumor size ≤3 cm ( P = 0.015), negative for lymph node metastasis ( P = 0.049), no tumor recurrence ( P = 0.021), and survival ( P = 0.042) had higher MVD. Survival analysis suggested that patients with high MVD had higher disease-free survival (log-rank P = 0.005) and overall survival (log-rank P = 0.004) compared to patients with low MVD. The Cox proportional hazards model showed that a high MVD ( P = 0.022) reduced the risk of postoperative tumor recurrence in patients with LUAD.
Conclusion
Decreased intratumoral CD34 positive microvessels were associated with tumor development in patients with LUAD. CD34-MVD is an independent risk factor affecting postoperative tumor recurrence in patients with LUAD and can be used as a prognostic indicator for this group of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.
- Department of Respiratory Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang, China.
- Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Pathology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Pathology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.
Zitieren
APA
Qiu, Z., Wu, J., Pang, G., Xu, X., Lin, J., & Wang, P. (2025). CD34 evaluation of microvasculature in lung adenocarcinoma and its microvascular density predicts postoperative tumor recurrence. Pathology and Oncology Research. https://doi.org/10.3389/pore.2025.1611985
Vancouver
Qiu Z, Wu J, Pang G, Xu X, Lin J, Wang P. CD34 evaluation of microvasculature in lung adenocarcinoma and its microvascular density predicts postoperative tumor recurrence. Pathology and Oncology Research. 2025. doi:10.3389/pore.2025.1611985
BibTeX
@article{Qiu2025,
author = {Qiu, Zijian and Wu, Jiaji and Pang, Guanchao and Xu, Xia and Lin, Jun and Wang, Pingli},
title = {CD34 evaluation of microvasculature in lung adenocarcinoma and its microvascular density predicts postoperative tumor recurrence},
journal = {Pathology and Oncology Research},
year = {2025},
doi = {10.3389/pore.2025.1611985}
}
EUVIMED